These findings suggest a new mechanism underlying hippocampal dysfunction and reveal the potential for treating multiple age-related diseases, including neurodegenerative disorders, obesity, diabetes, and atherosclerosis, with a single MT1-MMP-blocking agent. The gene discussed is MMP14; the disease is obesity due to melanocortin 4 receptor deficiency.